Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;28(5):243–246. doi: 10.1002/clc.4960280509

The effects of prior beta‐blocker therapy on serum C‐reactive protein levels after percutaneous coronary intervention

Ilyas Atar 1, Öykü Gülmez 1, Asli Atar 1,✉, Hüseyin Bozbas 1, Aylin Yildirir 1, Bülent Özin 1, Mehmet Emin Korkmaz 1, Haldun Müderrisoglu 1
PMCID: PMC6654617  PMID: 15971460

Abstract

Background: There are no studies in the literature related to the effect of beta blockers (BB) on changes in C‐reactive protein (CRP) levels after percutaneous coronary intervention (PCI).

Hypothesis: We designed a prospective randomized study to investigate the impact of BB therapy on CRP in patients who underwent elective PCI.

Methods: In all, 300 patients with coronary artery disease were included. Patients were randomized to either a metoprolol or to a control group before PCI. Blood samples for CRP levels were obtained before BB treatment, and at the 6th, 24th, and 36th h after PCI.

Results: Of 300 patients, 150 received metoprolol 100 mg/day (mean age, 59.0 ±10.2 years;106 men, 44 women), and 150 received no BB (mean age, 59.8±9.8years;114 men, 36 women) and served as the control group. Baseline clinical characteristics of both groups were similar. Basal CRP levels between the two groups were similar. Of the patients included in the study, 40.8% in the BB group and 39.6% in the control group had elevated basal CRP levels. The CRP levels increased above baseline values in 85% of patients in the BB group and in 89.3% of patients in the control group (p > 0.05) during follow‐up. The CRP levels in patients in the BB group at the 6th, 24th, and 36th h were lower than those in the control group; however, this difference did not reach statistical significance.

Conclusions: Prior BB therapy seems to have no effect on CRP levels after PCI.

Keywords: C‐reactive protein, beta blockers, percutaneous coronary intervention

Full Text

The Full Text of this article is available as a PDF (28.0 KB).

References

  • 1. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126 [DOI] [PubMed] [Google Scholar]
  • 2. Ridker PM, Glynn RJ, Hennekens CH: C‐reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007–2011 [DOI] [PubMed] [Google Scholar]
  • 3. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moyé LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–844 [DOI] [PubMed] [Google Scholar]
  • 4. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C‐reactive protein and serum amyloid, a protein in severe unstable angina. N Engl J Med 1994; 331: 417–424 [DOI] [PubMed] [Google Scholar]
  • 5. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A: Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370–2376 [DOI] [PubMed] [Google Scholar]
  • 6. Bazzino O, Diaz R, Tajer C, Paviotti C, Mele E, Trivi M, Piombo A, Prado AH, Paolasso E: Clinical predictors of in‐hospital prognosis in unstable angina: ECLA 3. The ECLA Collaborative Group. Am Heart J 1999; 137: 322–331 [DOI] [PubMed] [Google Scholar]
  • 7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979 [DOI] [PubMed] [Google Scholar]
  • 8. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–641 [DOI] [PubMed] [Google Scholar]
  • 9. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C‐reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–466 [DOI] [PubMed] [Google Scholar]
  • 10. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A: Preprocedural serum levels of C‐reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512–1521 [DOI] [PubMed] [Google Scholar]
  • 11. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG: Incremental prognostic value of elevated baseline C‐reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992–997 [DOI] [PubMed] [Google Scholar]
  • 12. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ: Inflammation and long‐term mortality after non‐ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 1412–1415 [DOI] [PubMed] [Google Scholar]
  • 13. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA: Predictive value of C‐reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000; 85: 92–95 [DOI] [PubMed] [Google Scholar]
  • 14. Gottsauner‐Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, Zorn G, Glogar D, Probst P, Maurer G, Huber K: Plasma levels of C‐reactive protein after coronary stent implantation. Eur Heart J 2000; 21: 1152–1158 [DOI] [PubMed] [Google Scholar]
  • 15. Walter DH, Fichtlscherer S, Sellwig M, Auch‐Schwelk W, Schachinger V, Zeiher AM: Preprocedural C‐reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839–846 [DOI] [PubMed] [Google Scholar]
  • 16. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, Gioffre PA: Predictive value of C‐reactive protein after successful coronary‐artery stenting in patients with stable angina. Am J Cardiol 1998; 82: 515–518 [DOI] [PubMed] [Google Scholar]
  • 17. Pepys MB: C‐reactive protein fifty years on. Lancet 1981; 1: 653–657 [DOI] [PubMed] [Google Scholar]
  • 18. Murray DR, Prabhu SD, Chandrasekar B: Chronic beta‐adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000; 101: 2338–2341 [DOI] [PubMed] [Google Scholar]
  • 19. Burger A, Benicke M, Deten A, Zimmer HG: Catecholamines stimulate in‐terleukin‐6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2001; 281: H14–21 [DOI] [PubMed] [Google Scholar]
  • 20. Doo YC, Kim DM, Oh DJ, Ryu KH, Rhim CY, Lee Y: Effect of beta blockers on expression of interleukin‐6 and c‐reactive protein in patients with unstable angina pectoris. Am J Cardiol 2001; 88: 422–424 [DOI] [PubMed] [Google Scholar]
  • 21. Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH: Beta‐blockers are associated with lower C‐reactive protein concentrations in patients with coronary artery disease. Am J Med 2002; 112: 269–274 [DOI] [PubMed] [Google Scholar]
  • 22. Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA: C‐reactive protein and ischemia in users and nonusers of beta‐blockers and statins: Data from the Heart and Soul Study. Circulation 2003; 107: 245–250 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, Satoh T, Mitamura H, Ogawa S: Early use of beta‐blockers is associated with attenuation of serum C‐reactive protein elevation and favorable short‐term prognosis after acute myocardial infarction. Cardiology 2003; 99: 47–53 [DOI] [PubMed] [Google Scholar]
  • 24. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SY, Serebruany VL, Gurbel PA, Gaulden LH, Felker GM, Whellan DJ, O'Connor CM: Effect of angiotensin‐converting enzyme inhibitors, beta blockers, statins, and aspirin on C‐reactive protein levels in outpatients with heart failure. Am J Cardiol 2004; 93: 783–785 [DOI] [PubMed] [Google Scholar]
  • 25. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long‐term effects of pravastatin on plasma concentration of C‐reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235 [DOI] [PubMed] [Google Scholar]
  • 26. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch‐Schwelk W, Schachinger V, Zeiher AM: Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38: 2006–2012 [DOI] [PubMed] [Google Scholar]
  • 27. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691–696 [DOI] [PubMed] [Google Scholar]
  • 28. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL: Statin therapy, lipid levels, C‐reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36: 1774–1780 [DOI] [PubMed] [Google Scholar]
  • 29. Albert MA, Danielson E, Rifai N, Ridker PM, and the PRINCE Investigators : Effect of statin therapy on C‐reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE):A randomized trial and cohort study. J Am Med Assoc 2001; 286: 64–70 [DOI] [PubMed] [Google Scholar]
  • 30. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, and the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators : Measurement of C‐reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–1965 [DOI] [PubMed] [Google Scholar]
  • 31. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K: Effect of beta‐blockers on circulating levels of inflammatory and anti‐inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 412–417 [DOI] [PubMed] [Google Scholar]
  • 32. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P: Effect of metoprolol on cytokine levels in chronic heart failure— a substudy in the Metoprolol Controlled‐Release Randomised Intervention Trial in Heart Failure (MERIT‐HF). Am Heart J 2001; 141: 418–421 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES